Agios Pharmaceuticals, Inc. AGIO NASDAQ

Agios Pharmaceuticals, Inc. (AGIO) generated $-372.98M in operating cash flow for fiscal year 2025. After capital expenditures of $4.32M, free cash flow was $-377.29M.

Free cash flow margin was -698.3% of revenue. Cash conversion ratio was 0.9x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (58/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.9x suggests some earnings are non-cash items

Overall SharesGrow Score: 58/100 with 3/7 criteria passed.